ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Price Down 10.7% - Here's Why

Key Points

• ChronoScale’s stock fell 10.7% to $15.96 in mid-day trading, with volume down 76% from its average.
• Analyst sentiment remains mixed: the consensus rating is “Hold” with an average price target of $19, though Northland Securities initiated coverage with an “Outperform” rating and a $32 target.
• The company reported a quarterly loss of $0.12 per share on $18.4 million in revenue, alongside a negative net margin of 135.66% and negative return on equity of 197.81%.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report)'s stock price was down 10.7% during mid-day trading on Tuesday. The company traded as low as $15.96 and last traded at $15.96. Approximately 54,431 shares were traded during trading, a decline of 76% from the average daily volume of 226,006 shares. The stock had previously closed at $17.88.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Northland Securities began coverage on ChronoScale Corporation Common Stock in a report on Friday, September 18th. They set an "outperform" rating and a $32.00 price objective on the stock. Weiss Ratings upgraded ChronoScale Corporation Common Stock from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ChronoScale Corporation Common Stock has a consensus rating of "Hold" and an average price target of $19.00.

ChronoScale Corporation Common Stock Stock Down 10.3%

The stock has a 50-day simple moving average of $20.31 and a two-hundred day simple moving average of $18.08. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.06. The firm has a market cap of $2.33 billion, a PE ratio of -2.98 and a beta of 0.98.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%. The firm had revenue of $18.40 million for the quarter.

Hedge Funds Weigh In On ChronoScale Corporation Common Stock

An institutional investor recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc increased its position in ChronoScale Corporation Common Stock (NASDAQ:CHRN - Free Report) by 104.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,338 shares of the company's stock after buying an additional 1,195 shares during the quarter. Roble Belko & Company Inc owned 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 6.42% of the stock is currently owned by institutional investors and hedge funds.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.